沃诺拉赞富马酸盐是一种新型的钾离子竞争性抑酸药,主要用于胃酸相关性疾病的治疗和预防,2014年在日本批准上市。与传统质子泵抑制药相比,具有众多优势,自上市后引起了广泛的关注并成为研究热点。本文从沃诺拉赞富马酸盐的临床疗效及不良反应等方面进行总结,以期为医护人员及患者提供最新信息。 Wano-nozuo fumarate is a novel potassium-acid competitive antacid which is mainly used for the treatment and prevention of gastric acid-related diseases. It was approved in Japan in 2014. Compared with the traditional proton pump inhibitors, it has many advantages and has aroused widespread concern and become a research hot spot after the market. This article summarizes the clinical efficacy and side effects of fura-novarnish fumarate in order to provide medical staff and patients with the latest information.